Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Iambic Therapeutics, Inc. Common Stock · IAM

IAMNASDAQCommon stockCurrentCIK 1997038Updated Nov 10, 2026

Company: Iambic Therapeutics, Inc. →

IAM price & chart

Provider market data

Loading TradingView…

NASDAQ:IAM on TradingView ↗

TradingView · Data may be delayed

About the company

We are a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry. Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation. We call this approach molecular superintelligence.

424B4 · 2026-10-15 · 0001193125-26-422865

Company description from the cited filing.

Offerings

Registration 333-299057

424B4 · 2026-10-15 · 0001193125-26-422865

Terms from the governing filing for this registration; not a claim that the offering is open today.

Gross proceeds
150000000.0
Net proceeds
139500000.0
Deal price
16.0
Shares
9375000
Offering price
$16.00
Ticker
IAM

Underwriters: J.P. Morgan Securities LLC, Jefferies LLC, BofA Securities, Inc., Citigroup Global Markets Inc.

Filing attachments

iam-ex4_1.htm · S-1 · 2026-09-21

Exhibit 4.1 IAMBIC THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 1, 2026, by and among Iambic Therapeutics, Inc., a Delaware corporation (the “Company”), the Key Holders (as defined below), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) tha…

S-1 · 2026-09-21 · 0001193125-26-396704

Read attachment ↗
iam-ex4_2.htm · S-1 · 2026-09-21

Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED. WARRANT TO PURCHASE STOCK Issuer: Entos, Inc., a Delaware corporation (the “Company”) Number of Shares: 1…

S-1 · 2026-09-21 · 0001193125-26-396704

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.